Equities

Redx Pharma PLC

Redx Pharma PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)18.50
  • Today's Change-0.25 / -1.33%
  • Shares traded62.90k
  • 1 Year change-40.32%
  • Beta-1.1311
Data delayed at least 20 minutes, as of Mar 28 2024 16:27 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Redx Pharma Plc is a United Kingdom-based clinical-stage biotechnology company. The Company is focused on the discovering and developing of novel, small molecule, targeted medicines for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis. The Company’s product pipeline includes RXC004, RXC007 (ROCK2 selective inhibitor) and RXC008. RXC004 is a potent, selective, oral small molecule inhibitor of the enzyme Porcupine, a key activator of Wnt-ligands in the Wnt signaling pathway. Selective ROCK2 inhibitor for the treatment of interstitial lung diseases with an initial study in idiopathic pulmonary fibrosis. RXC007 is a potent, selective and orally active inhibitor that targets Rho-Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2), which sits at a nodal point in cell signaling pathways, central to fibrosis. RXC008 for the treatment of fibrostenotic Crohn’s disease.

  • Revenue in GBP (TTM)4.20m
  • Net income in GBP-33.16m
  • Incorporated2010
  • Employees101.00
  • Location
    Redx Pharma PLCBlock 33, Mereside,, Alderley ParkMACCLESFIELD SK10 4TGUnited KingdomGBR
  • Phone+44 162 546 9900
  • Fax+44 151 706 4749
  • Websitehttps://www.redxpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Arecor Therapeutics PLC3.38m-9.42m42.11m51.00--3.19--12.46-0.3108-0.31080.11140.43140.1805--0.751666,254.90-50.32---66.40-------278.81--2.28--0.0125--107.51---50.11------
Venture Life Group PLC48.57m-756.00k46.49m153.00--0.62897.740.9571-0.0066-0.00660.36350.58440.43632.473.78317,477.10-0.6791.75-0.75722.0138.5640.30-1.564.411.551.370.23750.0034.2422.33-78.35--37.59--
Poolbeg Pharma PLC0.00-4.89m48.25m12.00--2.91-----0.0098-0.00980.000.03310.00----0.00-25.02---25.91--------------0.00-------100.60------
Celadon Pharmaceuticals PLC20.74k-8.06m52.97m----16.90--2,554.12-0.1306-0.13060.00030.04880.0016267.850.0248---64.68---71.16---29,080.42---40,384.18--1.84-12.450.6052--------------
Eco Animal Health Group Plc88.46m-1.62m56.91m228.00--0.697823.610.6433-0.024-0.0241.311.200.76641.923.41387,986.80-0.19496.03-0.26458.0243.0546.41-0.25447.892.261.220.043755.723.794.89246.94-35.90-4.43--
e-Therapeutics plc475.00k-8.27m65.15m38.00--1.96--137.17-0.0154-0.01540.00090.05680.0148--1.9212,500.00-25.79-33.25-27.10-35.11100.00100.00-1,741.90-1,490.90----0.0089---0.4193---2.53--24.22--
Redx Pharma PLC4.20m-33.16m72.93m101.00--18.72--17.36-0.099-0.0990.01260.010.0954--135.5541,603.96-75.26-52.99-166.19-88.10-----789.05-206.66----0.8405---77.52100.71-84.15--8.12--
Scancell Holdings Plc0.00-11.32m95.10m51.00---------0.0138-0.01380.00-0.01020.00----0.00-37.31-33.32-40.52-35.82-------817.98----1.73-------161.24--77.85--
Faron Pharmaceuticals Oy0.00-26.51m96.33m40.00---------0.4095-0.40950.00-0.21710.00-------287.97-213.06---963.12-----------12.02---------7.71---16.05--
Data as of Mar 28 2024. Currency figures normalised to Redx Pharma PLC's reporting currency: UK Pound GBX

Institutional shareholders

87.60%Per cent of shares held by top holders
HolderShares% Held
Redmile Group LLCas of 07 Nov 2023276.89m71.18%
Polar Capital LLPas of 07 Feb 202421.11m5.43%
Invus Public Equities Advisors LLCas of 07 Nov 202315.20m3.91%
AXA Investment Managers UK Ltd.as of 16 Mar 202012.29m3.16%
Hargreaves Lansdown Asset Management Ltd.as of 09 Mar 20208.45m2.17%
Platinum Investment Management Ltd.as of 08 Mar 20235.95m1.53%
IG Markets Ltd.as of 01 Feb 2024570.00k0.15%
HSBC Global Asset Management (UK) Ltd.as of 01 Feb 2024139.00k0.04%
Panmure Gordon (UK) Ltd.as of 01 Feb 202474.00k0.02%
Evelyn Partners Investment Management Services Ltd.as of 01 Feb 202472.00k0.02%
More ▼
Data from 31 Dec 2023 - 14 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.